

Please ~~amend~~ the specification as follows:

On page 1, after the title "Human Semaphorin 6A-1 (SEMA6A-A), A Gene Involved in Neuronal Development and Regeneration Mechanisms During Apoptosis, and Its Use as a Potential Drug Target", please add the following:

Prior Related Applications

A1
This application is the U. S. National Phase filing of International Application PCT/EP99/09215, with an international filing date of November 26, 1999, which claims priority to European Patent Application No. 98 122 441.3 filed November 26, 1998.

In The Claims:

Prior to examination of the application, please ~~cancel~~ Claims 1-21 and ~~add~~ the following new claim.

22. (New) Nucleic acid coding for human semaphorin 6A-1 comprising:
- (a) the nucleotide sequence shown in SEQ ID NO: 1,
 - (b) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 1 within the degeneration of the genetic code,
 - or
 - (c) a sequence which hybridizes with the sequences of (a) or/and
 - (b) under stringent conditions
- with the proviso that it contains a nucleic acid coding for a binding domain of human semaphorin 6A-1 comprising:
- (d) the nucleotide sequence shown in SEQ ID NO:3,

Serial No.: **To Be Assigned**

Attorney Docket No.: 48498-258443


Page 3

A2
could.

- (e) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO:3 within the degeneration of the genetic code, or
- (f) a sequence which hybridizes with the sequences of (d) or/and (e) under stringent conditions.

No additional fees are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to Deposit Account No. 11-0855.

Respectfully submitted,



John K. McDonald, Ph.D.

Reg. No. 42,860

KILPATRICK STOCKTON LLP
2400 Monarch Tower
3424 Peachtree Road
Atlanta, GA 30326
404-949-2400
Attorney Docket No. 48498-258443

0055661-080301
0055661-080301